Incremental net benefit value-based cost-effectiveness of mass vaccination of influenza vaccine: a systematic review and meta-analysis

李瑞,孙金芳,王莉娜,余小金

DOI: https://doi.org/10.11847/zgggws1121345

2019-01-01

Abstract:Objective To analyze the cost-effectiveness of mass vaccination of quadrivalent influenza vaccine (QIV) compared with that of trivalent influenza vaccine (TIV) using incremental net benefit (INB) method newly developed. Methods We searched four databases (PubMed, Web of science, Chinese National Knowledge Infrastructure [CNKI], and Wanfang Data Knowledge Service Platform) for literatures on cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine published from January 1998 to August 7th, 2018. We then conducted a meta-analysis using Stata/SE version 12.0 to estimate total incremental net benefit (TINB) of the QIV and TIV vaccination in targeted population. Results Totally 5 researches involving 96 727 891 participants were included in this study. The meta-analysis resulted in a combined TINB value of 308 (95% confidence interval [95% CI ]: 303 – 313) for all the QIV and TIV vaccinations under the assessment. After subtracting a research with small coefficient，the TINB of the researches was 307 (95% CI : 302 – 313) and very similar to that before the subgroup analysis, suggesting that a reliable result of the study. Publication bias may be resulted from the study due to the limitation in the number of literatures included in the study. Conclusion The mass vaccination of quadrivalent influenza vaccine is more cost-effective compared with that of trivalent influenza vaccine. 【摘 要】 目的 基于最新提出的成本效益指标净增效益值（INB）比较评价预防接种四价流感疫苗（QIV）与三价流感疫苗（TIV）的成本效益。 方法 检索中国知网数据库、万方数据知识服务平台、PubMed 数据库和 Web of science 数据库，收集 1998 年 1 月 1 日 — 2018 年 8 月 7 日公开发表的关于 QIV 与 TIV 成本效益比较的相关文献，应用 Stata/SE 12.0 软件进行 meta 分析，估计总增量净效益（TINB）。 结果 最终纳入 5 篇英文文献，累计研究对象 96 727 891 人；meta 分析结果显示，QIV 与 TIV 比较，合并的 TINB 为 308（95 % CI = 303～313）；在剔除权重系数较小的 1 个研究后合并的 TINB 为 307（95 % CI = 302～313），剔除前后研究的合并效益值比较接近，纳入的文献结果较为可靠。发表偏倚结果显示本研究所纳入文献可能存在发表偏倚，但因纳入的文献较少，发表偏倚的检验仍需作进一步研究。 结论 接种 QIV 与 TIV 相比更具有成本效益。